VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | The benefits of PET in the prognosis and treatment of HL

Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany discusses the applications of PET-CT in the prognosis and management of Hodgkin lymphoma (HL). Prof. Borchmann comments on how using PET allows for treatment personalization, and how total metabolic tumor volume (MTV) determination using PET is highly prognostic of patient outcomes. Moreover, the Phase III HD17 and HD18 trials (NCT01356680, NCT00515554) are discussed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter